The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 44-year-old man with well-controlled HIV on an antiretroviral regimen containing cobicistat-boosted elvitegravir presents to the PMHNP for evaluation of worsening depressive symptoms. He reports persistent low mood, anhedonia, fatigue, difficulty concentrating, and insomnia over the past six weeks. His CD4 count is 520 cells/mm3 and his viral load is undetectable. He has no prior psychiatric history but describes significant psychosocial stressors including HIV-related stigma, disclosure concerns, and anticipatory grief regarding his diagnosis. The PMHNP considers the assessment and treatment planning for this patient. Which of the following most accurately reflects the clinical considerations for psychiatric care in this population?
Explanation
Depression prevalence in HIV-positive individuals is two to three times that of the general population, with multifactorial etiology involving neuroinflammation, psychosocial stressors, and potential medication effects. Cobicistat is a potent CYP3A4 inhibitor creating clinically significant interactions with many psychotropic medications. Comprehensive psychiatric assessment must address both neurobiological and psychosocial contributors to depression in this population.
Key Takeaway
Psychiatric care for HIV-positive patients requires awareness of CYP3A4 inhibition by cobicistat and other pharmacokinetic enhancers, the multifactorial nature of depression in HIV including neuroinflammation and stigma, and the two- to three-fold increased depression prevalence in this population.